Mereo BioPharma Group plc (MREO) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 5 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for MREO is $0.83, representing a +153.3% upside from the current price of $0.329. Price targets range from a low of $0.50 to a high of $1.00.
